Feroz Noori, MD
Pulmonary Disease · Martinsburg, WVNPI 1487815320
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (49.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Intuitive Surgical at 38.5% of the total. Reporting peaked in 2021 at $2,124 and has fallen 98.7% since, to $29 in 2025.
Across 38 payments — averaging $81.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- Takeda Pharmaceuticals U.S.A., Inc.$844
- Olympus Corporation Of The Americas$569
- Mallinckrodt Hospital Products Inc.$200
- Baxter Healthcare$100
- AstraZeneca$82
- plus $116 from 2 others
What the payments were for
- Consulting fees$82527%
- Travel & lodging$1,53849%
- Food & beverage$51417%
- Education$2348%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 14 | $1,199 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $844 |
| Olympus Corporation Of The Americas | 6 | $569 |
| Mallinckrodt Hospital Products Inc. | 2 | $200 |
| Baxter Healthcare | 3 | $100 |
| AstraZeneca | 5 | $82 |
| GSK | 4 | $68 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,110 in reported general payments places this provider in the 65th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlassiaAlpha-1-Proteinase Inhibitor | 26 | $191,966 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $71,552 |
| TezspireTezepelumab-Ekko | 12 | $52,782 |
| Dupixent SyringeDupilumab | 12 | $44,829 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $20,241 |
| Spiriva RespimatTiotropium Bromide | 29 | $19,828 |
| Spiriva HandihalerTiotropium Bromide | 15 | $15,839 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $12,866 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $4,609 |
| Arnuity ElliptaFluticasone Furoate | 18 | $3,547 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 76 | $2,581 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $1,928 |
| Montelukast Sodium | 70 | $1,068 |
| Roflumilast | 12 | $1,065 |
| Fluticasone Propionate | 16 | $126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $844 | $191,96626 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $68 | $95,340117 claims |
| AstraZenecaTezspire, Symbicort, Bevespi Aerosphere | $82 | $70,25748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Martinsburg
- Phillip AguilaMartinsburg$21K
- Houssein YounessMartinsburg$10K
- Richard CatlettMartinsburg$3K
- Hafiz Muhammad ZubairMartinsburg$2K
- Melvin SaludesGlen Dale$255K
- Roger AbrahamsMorgantown$133K
- Maria BoustaniBeckley$95K
- Ramzi HaddadinBeckley$43K
- Salam RajjoubBridgeport$29K
- Peter KochupuraMorgantown$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.